Bayer AG CEO Bill Anderson's ambitious plan to resolve the company's long-running Roundup litigation with a $7 billion settlement is encountering resistance from investors. The German pharmaceutical and agricultural giant has been entangled in thousands of lawsuits alleging its glyphosate-based herbicide causes cancer, creating a significant financial and reputational burden.

The proposed settlement aims to put an end to the protracted legal battles that have plagued Bayer since its 2018 acquisition of Monsanto, the original manufacturer of Roundup. Despite the substantial financial commitment, some investors question whether this approach adequately addresses the company's exposure and whether the settlement terms are favorable enough to provide lasting relief from the litigation cloud.

Anderson's strategy represents a major shift in Bayer's approach to the Roundup controversy, moving from aggressive legal defense to settlement negotiations. The skepticism from the investment community suggests concerns about the settlement's structure, potential ongoing liabilities, and whether $7 billion sufficiently caps the company's financial exposure to future claims. The outcome of this effort will significantly impact Bayer's financial position and strategic direction in the agricultural sector.